AVP and abnormal glucose tolerance: In an age- and gender-matched study of 166 patients with AMI without known diabetes, who were followed for 11.6 years [72], copeptin was higher in patients vs. controls (10.5 vs. 5.9 ng/mL, p < 0.01), as well as in patients with abnormal glucose tolerance vs. patients with normal glucose tolerance (12.2 vs. 7.9 ng/mL, p < 0.01).